Delivery of anti-angiogenic molecular therapies for retinal disease

Drug Discovery Today

Volumn 15, Issue 7-8, 2010, Pages 272-282

  Anderson, Owen A ^a   Bainbridge, James W B ^a   Shima, David T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADENOVIRUS VECTOR; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BROMFENAC; DEXAMETHASONE; DOXYCYCLINE; ECALLANTIDE; EVEROLIMUS; FLUOCINOLONE; INFLIXIMAB; JSM 6427; MECAMYLAMINE; MP 0112; NEPAFENAC; OCTREOTIDE; PARVOVIRUS VECTOR; PAZOPANIB; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR INHIBITOR; PYRROLIDINE DERIVATIVE; RANIBIZUMAB; RAPAMYCIN; RUBOXISTAURIN; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; VOLOCIXIMAB;

ANTIANGIOGENIC THERAPY; BLINDNESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MOLECULAR THERAPY; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SUSTAINED RELEASE PREPARATION;

ABSORBABLE IMPLANTS; ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GENE THERAPY; HUMANS; INJECTIONS; RETINAL DISEASES; VITREOUS BODY;

EID: 77950924888     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.02.004     Document Type: Review

References (78)

1. Steinkuller P.G., et al. Childhood blindness. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 1999, 3:26-32.
2. Rahmani B., et al. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 1996, 103:1721-1726.
3. Bressler N.M., Bressler S.B. Preventative ophthalmology. Age-related macular degeneration. Ophthalmology 1995, 102:1206-1211.
4. Del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 2008, 13:135-143.
5. Hori Y., et al. Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Br. J. Pharmacol. 1996, 118:1584-1591.
6. Gragoudas E.S., et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816.
7. Kourlas H., Schiller D.S. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin. Ther. 2006, 28:36-44.
8. Ruckman J., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998, 273:20556-20567.
9. Rosenfeld P.J., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
10. Brown D.M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444.
11. The Royal College of Ophthalmologists (2008) Guidelines for Ranibizumab - the Clinician's Guide to commencing, continuing and discontinuing treatment (). http://www.rcophth.ac.uk/about/publications.
12. Bakri S.J., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007, 114:2179-2182.
13. Riely G.J., Miller V.A. Vascular endothelial growth factor Trap in non small cell lung cancer. Clin. Cancer Res. 2007, 13:s4623-s4627.
14. Holash J., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11393-11398.
15. Nguyen Q.D., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113. 1522.e1-1522.e14.
16. Ambati J., et al. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 2000, 41:1181-1185.
17. Wang W., et al. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res. 1991, 10:571-579.
18. Maurice D. Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. 2001, 17:393-401.
19. Liu W., et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob. Agents Chemother. 1998, 42:1417-1423.
20. la Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?. Acta Ophthalmol. Scand. 2007, 85:2-4.
21. Presta L.G., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-4599.
22. Stewart M.W., Rosenfeld P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008, 92:667-668.
23. Driot J.Y., et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther. 2004, 20:269-275.
24. Bourges J.L., et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Rev. 2006, 58:1182-1202.
25. Pearson P., et al. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial (Abstract). Invest. Ophthalmol. Vis. Sci. 2006, 47:5442.
26. Shane T.S., Martin D.F. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 2003, 136:649-654.
27. Dunn J.P., et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 2004, 24:41-50.
28. Kimura H., Ogura Y. Biodegradable systems. Intraocular Drug Delivery 2006, 175-192. Informa Healthcare. 1st ed. G.J. Jaffe (Ed.).
29. Kunou N., et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release 2000, 68:263-271.
30. Hsu J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol. 2007, 18:235-239.
31. Moritera T., et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1992, 33:3125-3130.
32. Moshfeghi A.A., Peyman G.A. Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 2005, 57:2047-2052.
33. Lavinsky D., et al. Phase I/II study of intravitreal triamcinolone acetonide microspheres for treatment of diffuse diabetic macular edema unresponsive to conventional laser photocoagulation treatment. Invest. Ophthalmol. Vis. Sci. 2008, 49. E-Abstract 2698 (online).
34. Li H., et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res. 2006, 83:824-833.
35. Schmidt P.G., et al. PEGylated bioactive molecules in biodegradable polymer microparticles. Expert Opin. Biol. Ther. 2007, 7:1427-1436.
36. Vandervoort J., Ludwig A. Ocular drug delivery: nanomedicine applications. Nanomedicine 2007, 2:11-21.
37. Doukas J., et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J. Cell. Physiol. 2008, 216:29-37.
38. Lee V.H., Robinson J.R. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 1986, 2:67-108.
39. Prausnitz M.R., Noonan J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998, 87:1479-1488.
40. Hamalainen K.M., et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Vis. Sci. 1997, 38:627-634.
41. Fitzgerald P., et al. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. J. Pharm. Pharmacol. 1987, 39:487-490.
42. Kim S.H., et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007, 39:244-254.
43. Anderson O.A., et al. Human transscleral albumin permeability and the effect of topographical location and donor age. Invest. Ophthalmol. Vis. Sci. 2008, 49:4041-4045.
44. Robinson M.R., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 2006, 82:479-487.
45. Pontes de Carvalho R.A., et al. Delivery from episcleral exoplants. Invest. Ophthalmol. Vis. Sci. 2006, 47:4532-4539.
46. Bill A. The drainage of albumin from the uvea. Exp. Eye Res. 1964, 3:179-187.
47. Kim H., et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 2004, 45:2722-2731.
48. Kato A., et al. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. 2004, 45:238-244.
49. Okabe J., et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 2003, 44:740-744.
50. Okabe K., et al. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 2003, 44:2702-2707.
51. Gilger B.C., et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest. Ophthalmol. Vis. Sci. 2006, 47:2596-2605.
52. Olsen T.W., et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 2006, 142:777-787.
53. Bochot A., et al. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J. Drug Target. 1998, 6:309-313.
54. Carrasquillo K.G., et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. 2003, 44:290-299.
55. Voigt M., et al. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun. 2002, 295:336-341.
56. Parkinson T.M., et al. Tolerance of ocular iontophoresis in healthy volunteers. J. Ocul. Pharmacol. Ther. 2003, 19:145-151.
57. Halhal M., et al. Iontophoresis: from the lab to the bed side. Exp. Eye Res. 2004, 78:751-757.
58. Eljarrat-Binstock E., et al. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J. Control. Release 2008, 126:156-161.
59. Dufes C., et al. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 2005, 57:2177-2202.
60. Bejjani R.A., et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 2005, 11:124-132.
61. Bainbridge J.W., et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 2002, 9:320-326.
62. Pechan P., et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009, 16:10-16.
63. Reichel M.B., et al. Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther. 1998, 5:1038-1046.
64. Kuo C.J., et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4605-4610.
65. Campochiaro P.A., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 2006, 17:167-176.
66. Mori K., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 2002, 43:2428-2434.
67. Gehlbach P., et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 2003, 10:637-646.
68. Saishin Y., et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum. Gene Ther. 2005, 16:473-478.
69. Bainbridge J.W., et al. Gene therapy for ocular angiogenesis. Clin. Sci. (Lond.) 2003, 104:561-575.
70. Bainbridge J.W., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2231-2239.
71. Cideciyan A.V., et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15112-15117.
72. Maguire A.M., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2240-2248.
73. McGee Sanftner L.H., et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol. Ther. 2001, 3:688-696.
74. Auricchio A., et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol. Ther. 2002, 6:238-242.
75. Bainbridge J.W., et al. Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization. Gene Ther. 2003, 10:1049-1054.
76. Sieving P.A., et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3896-3901.
77. Uteza Y., et al. Intravitreous transplantation of encapsulated fibroblasts secreting the human fibroblast growth factor 2 delays photoreceptor cell degeneration in Royal College of Surgeons rats. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3126-3131.
78. Hoane M.R., et al. Mammalian-cell-produced neurturin (NTN) is more potent than purified Escherichia coli-produced NTN. Exp. Neurol. 2000, 162:189-193.